A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Drug repurposing is an effective strategy to identify new uses for existing drugs, providing the quickest possible transition from bench to bedside. Real-world data, such as electronic health records and insurance claims, provide information on large cohorts of users for many drugs. Here we present an efficient and easily customized framework for generating and testing multiple candidates for drug repurposing using a retrospective analysis of real-world data. Building upon well-established causal inference and deep learning methods, our framework emulates randomized clinical trials for drugs present in a large-scale medical claims database. We demonstrate our framework on a coronary artery disease cohort of millions of patients. We successfully identify drugs and drug combinations that substantially improve the coronary artery disease outcomes but haven’t been indicated for treating coronary artery disease, paving the way for drug repurposing. Many approved drugs can be used to treat diseases other than the one they were developed for, which has the added benefit that the safety of the drug has already been tested. To identify possible candidates for re-purposing trials, Liu et al. have developed a method to use existing electronic patient data to simulate clinical trials and identify drugs that influence the progression of diseases with which they were not previously associated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Speech recognition with deep recurrent neural networks
Graves, A., Mohamed, A.-R., & Hinton, G. (2013) · 2013 IEEE International Conference on Acoustics, Speech and Signal Processing · doi:10.1109/icassp.2013.6638947 · Cited by 8,893
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
Cited by
Artificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 498
AI-powered therapeutic target discovery
Pun, F. W., Ozerov, I. V., & Zhavoronkov, A. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.010 · Cited by 341
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Zang, C., Zhang, H., Xu, J., Zhang, H., Fouladvand, S., Havaldar, S., Cheng, F., Chen, K., Chen, Y., Glicksberg, B. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43929-1 · Cited by 69
“We compared the analytic approach by Liu et al. 7 and we found that their methods led to biased SMD estimation and worse balance performance as shown in Supplementary Table S2 due to their deep LSTM-PS methods.”
InfluentialSuccess stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Artificial intelligence for dementia prevention
Newby, D., Orgeta, V., Marshall, C. R., Lourida, I., Albertyn, C. P., Tamburin, S., Raymont, V., Veldsman, M., Koychev, I., Bauermeister, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13463 · Cited by 42
“Opportunities and future directions for ML to enhance prevention interventions and trials”
Background
Metadata
- Authors
- Liu, R., Wei, L., & Zhang, P.
- Venue
- Nature Machine Intelligence
- Published
- 2021-01-04
- Volume
- 3
- Issue
- 1
- Pages
- 68-75
- ISSN
- 2522-5839 (ISSN-L)
- OpenAlex
- W3120049458
- Cited by
- 117
- References
- 16
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. https://app.cochat.ai/papers/10.1038/s42256-020-00276-w
- The paper
- Liu, R., Wei, L., & Zhang, P. (2021). A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. Nature Machine Intelligence. https://doi.org/10.1038/s42256-020-00276-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.